FIELD: medicine.
SUBSTANCE: there are examined a recovered monoclonal antibodies which binds human or Cynomolgus monkey antibodies IL-17F and IL-17A, and its antigen-binding fragment. There are offered: pharmaceutical compositions comprising the antibody under the invention, as well as a method for relieving manifestations of a clinical symptom associated with rheumatoid arthritis, regional enteritis, psoriasis, multiple sclerosis, chronic obstructive pulmonary disease or asthma, and a method for relieving symptoms of autoimmune disease, inflammatory disorders or cell proliferation disorders based on the use of the antibody under the invention.
EFFECT: use may find further application in treating the diseases related to IL-17F and 1L-17A.
16 cl, 9 ex, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IL-17F ANTIBODIES AND METHODS FOR USE THEREOF | 2010 |
|
RU2605318C2 |
| TRISPECIFIC IL-17A, IL-17F AND OTHER PROINFLAMMATORY MOLECULES ANTIBODIES | 2016 |
|
RU2680011C2 |
| USE OF IL-17 ANTAGONISTS FOR INHIBITION OF STRUCTURAL DAMAGE PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS | 2015 |
|
RU2697383C2 |
| IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
| NEW INDICATIONS FOR USE IN TREATING ANTIBODIES AGAINST IL-1-BETA | 2014 |
|
RU2698208C2 |
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2582937C2 |
| HUMAN ANTIBODIES TO IL-β1 | 2001 |
|
RU2286351C2 |
| METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2591083C2 |
| NOVEL APPLICATION OF IL-1β COMPOUNDS | 2012 |
|
RU2571563C2 |
